Evidence map›Paper›PMID 38391624›Full record

ReviewBioengineering (Basel, Switzerland)2024

Advances and Challenges in Wearable Glaucoma Diagnostics and Therapeutics.

Ryan Shean, Ning Yu, Sourish Guntipally, Van Nguyen, Ximin He, Sidi Duan, Kimberly Gokoffski, Yangzhi Zhu, Benjamin Xu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Artificial intelligence in ophthalmology clinical trials: a narrative review.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Meeting Challenges in the Diagnosis and Treatment of Glaucoma.Bioengineering (Basel, Switzerland) · 2024
    Article
  8. Review
  9. Review
  10. Article
  11. Early diagnostics and interventional glaucoma.Therapeutic advances in ophthalmology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ryan SheanKeck School of Medicine, University of Southern California, 1975 Zonal Avenue, Los Angeles, CA 90033, USA.ORCID 0000-0002-2831-8040
Ning YuDepartment of Chemical Engineering, Stanford University, Stanford, CA 94305, USA.
Sourish GuntipallyTerasaki Institute for Biomedical Innovation, 21100 Erwin Street, Los Angeles, CA 90064, USA.
Van NguyenRoski Eye Institute, Keck School of Medicine, University of Southern California, 1450 San Pablo Street, Los Angeles, CA 90033, USA.ORCID 0000-0002-5961-4280
Ximin HeDepartment of Materials Science and Engineering, University of California, 410 Westwood Plaza, Los Angeles, CA 90095, USA.
Sidi DuanDepartment of Materials Science and Engineering, University of California, 410 Westwood Plaza, Los Angeles, CA 90095, USA.
Kimberly GokoffskiRoski Eye Institute, Keck School of Medicine, University of Southern California, 1450 San Pablo Street, Los Angeles, CA 90033, USA.
Yangzhi ZhuTerasaki Institute for Biomedical Innovation, 21100 Erwin Street, Los Angeles, CA 90064, USA.ORCID 0000-0003-2920-3365
Benjamin XuRoski Eye Institute, Keck School of Medicine, University of Southern California, 1450 San Pablo Street, Los Angeles, CA 90033, USA.
University of Southern California · USTerasaki Foundation · USUniversity of California, Riverside · US

Funding

Development and Validation of Quantitative Anterior Segment OCT-based Methods to Evaluate Patients with Primary Angle Closure DiseaseK23EY029763 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI XU, BENJAMIN Y. · 2019 to 2023
$1.1M
NEI NIH HHS K23 EY029763
6 · The paper itself

Abstract

Glaucoma is a leading cause of irreversible blindness, and early detection and treatment are crucial for preventing vision loss. This review aims to provide an overview of current diagnostic and treatment standards, recent medical and technological advances, and current challenges and future outlook for wearable glaucoma diagnostics and therapeutics. Conventional diagnostic techniques, including the rebound tonometer and Goldmann Applanation Tonometer, provide reliable intraocular pressure (IOP) measurement data at single-interval visits. The Sensimed Triggerfish and other emerging contact lenses provide continuous IOP tracking, which can improve diagnostic IOP monitoring for glaucoma. Conventional therapeutic techniques include eye drops and laser therapies, while emerging drug-eluting contact lenses can solve patient noncompliance with eye medications. Theranostic platforms combine diagnostic and therapeutic capabilities into a single device. Advantages of these platforms include real-time monitoring and personalized medication dosing. While there are many challenges to the development of wearable glaucoma diagnostics and therapeutics, wearable technologies hold great potential for enhancing glaucoma management by providing continuous monitoring, improving medication adherence, and reducing the disease burden on patients and healthcare systems. Further research and development of these technologies will be essential to optimizing patient outcomes.

Indexed as

diagnosticsglaucomasmart contact lenstheranosticstherapeutics

Identifiers

PMID38391624
PMCPMC10886103
OpenAlexW4391350161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.